Fennec Announces Pricing of Public Offering
December 08 2017 - 7:54AM
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a
biotechnology company focused on the development of PEDMARKTM (a
unique formulation of sodium thiosulfate (STS)) for the prevention
of platinum-induced ototoxicity from cisplatin in pediatric cancer
patients, today announced the pricing of its underwritten public
offering of 2,352,950 common shares at a public offering price of
$8.50 per share. In addition, Fennec has granted the underwriters a
30-day option to purchase up to an additional 352,942 common
shares. Fennec anticipates the total gross proceeds from the
offering (before deducting the underwriting discounts and offering
expenses) will be approximately $20 million, excluding any exercise
of the underwriters’ option to purchase additional shares. The
offering is expected to close on December 12, 2017, subject to
customary closing conditions.
Wedbush PacGrow is acting as the sole book-running manager for
the proposed offering. H.C. Wainwright & Co. is acting as the
co-manager.
Fennec plans to use the net proceeds from this offering for
obtaining regulatory approvals, the potential launch of PEDMARKTM,
and working capital and general corporate purposes.
The common shares are being offered by the Company pursuant to a
registration statement previously filed with and declared effective
by the Securities and Exchange Commission (the “SEC”). The offering
will be made only by means of a prospectus. A final prospectus
supplement and an accompanying prospectus relating to the offering
will be filed with the SEC and will be available on the SEC’s
website located at http://www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus, when filed
with the SEC, may also be obtained from Wedbush Securities Inc.,
Two Embarcadero Center, Suite 600, San Francisco, CA 94111, Attn:
ECM Prospectus Department, by calling 415-274-6819, or by email at
Vinnie.Devone@wedbush.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction. The securities will not be offered or
sold, directly or indirectly, in Canada or to any resident of
Canada.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. The offering is subject to market and other conditions and
there can be no assurance as to whether or when the offering may be
completed or as to the actual size or terms of the offering. These
forward-looking statements are subject to risks and uncertainties
that may cause the company’s actual activities or results to differ
materially from those expressed or implied in such forward-looking
statements, including risks and uncertainties described under the
heading “Risk Factors” in documents the company files from time to
time with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release, and the company undertakes no obligation to revise or
update any forward-looking statements to reflect events or
circumstances after the date hereof.
About PEDMARK™ (Sodium Thiosulfate
(STS))
Cisplatin and other platinum compounds are essential
chemotherapeutic components for many pediatric
malignancies. Unfortunately, platinum-based therapies cause
ototoxicity in many patients, and are particularly harmful to the
survivors of pediatric cancer.
In the U.S. and Europe there is estimated that over 7,000
children are diagnosed with low-to-intermediate risk cancers that
may receive platinum based chemotherapy. Low-to-intermediate
risk cancers that receive platinum agents may have overall survival
rates of greater than 80% further emphasizing the quality of life
after treatment. The incidence of hearing loss in these children
depends upon the dose and duration of chemotherapy, and many of
these children require lifelong hearing aids. There is currently no
established preventive agent for this hearing loss and only
expensive, technically difficult and sub-optimal cochlear (inner
ear) implants have been shown to provide some benefit. Infants and
young children at critical stages of development lack speech
language development and literacy, and older children and
adolescents lack social-emotional development and educational
achievement.
STS has been studied by cooperative groups in two Phase 3
clinical studies of survival and reduction of ototoxicity, The
Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both
studies are closed to recruitment. The COG ACCL0431 protocol
enrolled one of five childhood cancers typically treated with
intensive cisplatin therapy for localized and disseminated disease,
including newly diagnosed hepatoblastoma, germ cell tumor,
osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6
enrolled only hepatoblastoma patients with localized tumors.
About Fennec PharmaceuticalsFennec
Pharmaceuticals Inc., is a specialty pharmaceutical company focused
on the development of PEDMARK™ for the prevention of
platinum-induced ototoxicity in pediatric patients. STS has
received Orphan Drug Designation in the US in this setting. For
more information, please visit www.fennecpharma.com.
ContactRosty RaykovChief Executive
OfficerFennec Pharmaceuticals Inc.T: (919) 636-5144
Fennec Pharmaceuticals (TSX:FRX)
Historical Stock Chart
From Apr 2024 to May 2024
Fennec Pharmaceuticals (TSX:FRX)
Historical Stock Chart
From May 2023 to May 2024